Remedy Robotics raises $62M to take its remote stroke-procedure robot toward a pivotal trial
DCVC led the Series B for the San Francisco company, whose N1 System is built to run endovascular procedures on-site, remotely or autonomously. The money funds a planned pivotal trial across the University of California network.

- Amount
- $62M
- Type
- Series B
- Company
- Remedy Robotics
- Lead investor
- DCVC
- Sector
- Medtech
- Announced
- Nov. 16, 2026
Endovascular care for stroke and other cardiovascular emergencies is available at relatively few hospitals, because it takes highly trained specialists, according to Remedy Robotics. The San Francisco company is building a robot to widen that reach, and it said Nov. 16 that it raised $62 million in a Series B.
DCVC led the round. New investors include UC Investments, the University of California's investment office; Skip Capital; and Hostplus, which the company described as one of Australia's largest pension funds. Existing backers Build Collective by Tony Fadell, Blackbird, Divergent Capital and KdT Ventures put in more. Remedy did not disclose a valuation or its total funding to date.
Why it matters: Remedy is building a robot meant to let catheter-based procedures be done without the specialist in the room, an attempt to widen where stroke and heart emergencies can be treated. The company said in its announcement that only 2.8% of stroke patients worldwide who qualify for endovascular treatment can get it.
What the money is for
The round funds a planned pivotal clinical trial run with the University of California, along with work toward an FDA marketing decision for neurovascular procedures, the company said. Remedy also plans to place prototype N1 Systems with clinical partners, including through its tie-ups with SVIN Mission Thrombectomy and the Australian Stroke Alliance, and to keep developing the system's autonomous functions.
Jake Sganga, the chief technology officer and a co-founder, said the company has worked with University of California clinicians since 2021, and that the pivotal trials are planned across the UC network.
How the N1 works
Remedy describes the N1 as a robot paired with software that applies machine learning to pre-procedure scans, rehearses cases ahead of time, aligns 3D and 2D images during the procedure and performs the full endovascular procedure robotically. The company says the system can be run beside the patient, from a distance or on its own, and is aimed at vessels in the brain, the heart and the rest of the body.
The system is still in development. Remedy said the N1 is not available for sale or for clinical use in any jurisdiction.
In October 2025, Remedy said that Vitor Mendes Pereira, a physician at Unity Health Toronto, used the N1 to perform neurointerventional procedures robotically and remotely, operating from St. Joseph's Health Centre while the patients were at St. Michael's Hospital across the city. The company said those procedures needed no interventionist at the bedside.
"This funding will allow us to accelerate toward deployment of our N1 System so we can bring quality intervention to patients everywhere, regardless of geography," said David Bell, Remedy's chief executive and co-founder.
Remedy said it has more than 100 hospital relationships around the world and holds 48 patents.
What comes next
Surgical robotics has drawn large private rounds this fall, including MMI's $125 million Series D for its microsurgery robot in October. Remedy's own next marker is the start of its pivotal trial in the UC network. The company did not say when enrollment would begin or which FDA pathway it will pursue.



